Cancer Family
Neuroepithelial Neoplasm
CI-CAN-00000287Explore in graph →
Non-malignant812 active trials6 approved drugs154 evidence items
Loading cancer entity…
Cancer Family
CI-CAN-00000287Explore in graph →
Clinical trials
2,936 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07530458 | Retinoblastoma Consolidation in Egyptians | not yet recruiting | — | 150 | Assiut UniversityOTHER | 0 | Apr 15, 2026 | clinicaltrials |
| NCT07532031 | APT-weighted and Diffusion MRI for Characterizing Tumor Infiltration in High-Grade Gliomas(APT-HGG) | not yet recruiting | — | 20 | IRCCS Ospedale San RaffaeleOTHER | 0 | Apr 15, 2026 |
| NCT06512311 | Personalized Targeted Glioblastoma Therapies by ex Vivo Drug Screening(ATTRACT) | recruiting | N/A | 240 | Medical University of ViennaOTHER | 1 | Apr 14, 2026 | clinicaltrials |
| NCT07185880 | A Phase 1/2 Study of the Safety and Tolerability of MT-125 in GBM Patients(STAR-GBM) | recruiting | Phase 1 / Phase 2 | 36 | Myosin Therapeutics Inc.INDUSTRY | 1 | Apr 14, 2026 | clinicaltrials |
| NCT02800486 | Super Selective Intra-arterial Repeated Infusion of Cetuximab (Erbitux) With Reirradiation for Treatment of Relapsed/Refractory GBM, AA, and AOA | recruiting | Phase 2 | 37 | Northwell HealthOTHER | 1 | Apr 13, 2026 | clinicaltrials |
| NCT04185038 | Study of B7-H3-Specific CAR T Cell Locoregional Immunotherapy for Diffuse Intrinsic Pontine Glioma/Diffuse Midline Glioma and Recurrent or Refractory Pediatric Central Nervous System Tumors | recruiting | Phase 1 | 90 | Seattle Children's HospitalOTHER | 1 | Apr 13, 2026 | clinicaltrials |
| NCT04528680 | Ultrasound-based Blood-brain Barrier Opening and Albumin-bound Paclitaxel and Carboplatin for Recurrent Glioblastoma(SC9/ABX) | active not recruiting | Phase 1 / Phase 2 | 57 | Northwestern UniversityOTHER | 1 | Apr 13, 2026 | clinicaltrials |
| NCT05168423 | CART-EGFR-IL13Ra2 in EGFR Amplified Recurrent GBM | active not recruiting | Phase 1 | 67 | University of PennsylvaniaOTHER | 1 | Apr 13, 2026 | clinicaltrials |
| NCT06419946 | Lomustine in Addition to Standard of Care in Patients With MGMT Methylated Glioblastoma | recruiting | Phase 3 | 200 | Vastra Gotaland RegionOTHER_GOV | 4 | Apr 13, 2026 | clinicaltrials |
| NCT06810544 | Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss | recruiting | Phase 1 / Phase 2 | 191 | Tango Therapeutics, Inc.INDUSTRY | 1 | Apr 13, 2026 | clinicaltrials |
| NCT07134842 | A Study Assessing if it is Safe and Possible to Treat Brain Cancer Patients With Immunotherapy Before They Receive the Standard Treatment.(WinGlio-ipi) | recruiting | Phase 1 | 16 | University College, LondonOTHER | 1 | Apr 9, 2026 | clinicaltrials |
| NCT02104310 | A Pilot Study Using 18F-DOPA PET-guided Radiotherapy in Gliomas | active not recruiting | — | 25 | Mayo ClinicOTHER | 1 | Apr 6, 2026 | clinicaltrials |
| NCT07488754 | Local, Targeted Therapy With Alpha Emitter [225Ac]Ac-DOTA-SP (TAT) In Newly Diagnosed Glioma (WHO G3-G4) | recruiting | N/A | 35 | Medical University of WarsawOTHER | 1 | Apr 6, 2026 | clinicaltrials |
| NCT07511725 | Prophylactic Regimen With Intrathecal Thiotepa in SVZ-positive or Meningeal-risk Glioblastoma(PRISM) | recruiting | Phase 2 | 38 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Apr 6, 2026 | clinicaltrials |
| NCT03678883 | 9-ING-41 in Patients With Advanced Cancers | active not recruiting | Phase 2 | 350 | Actuate Therapeutics Inc.INDUSTRY | 7 | Apr 3, 2026 | clinicaltrials |
| NCT05789394 | Allogenic Adipose-Derived Mesenchymal Stem Cells for the Treatment of Recurrent Glioblastoma or Recurrent Astrocytoma in Patients Undergoing Craniotomy | recruiting | Phase 1 | 20 | Mayo ClinicOTHER | 1 | Apr 2, 2026 | clinicaltrials |
| NCT07417761 | Tuvusertib in Astrocytoma With ATRX Mutation(TUVASTRAT) | recruiting | Phase 2 | 56 | Grupo Español de Investigación en NeurooncologíaOTHER | 1 | Apr 2, 2026 | clinicaltrials |
| NCT07506239 | Efficacy of Laser Interstitial Thermal Therapy in Young Persons With Low-grade Glioma | recruiting | N/A | 40 | University of California, San FranciscoOTHER | 1 | Apr 1, 2026 | clinicaltrials |
| NCT05986851 | Azeliragon in MGMT Unmethylated Glioblastoma | active not recruiting | Phase 2 | 30 | Cantex PharmaceuticalsINDUSTRY | 1 | Mar 31, 2026 | clinicaltrials |
| NCT03596086 | HSV-tk + Valacyclovir + SBRT + Chemotherapy for Recurrent GBM | recruiting | Phase 1 / Phase 2 | 62 | David Baskin MDOTHER | 1 | Mar 30, 2026 | clinicaltrials |
| NCT03603405 | HSV-tk and XRT and Chemotherapy for Newly Diagnosed GBM | recruiting | Phase 1 / Phase 2 | 62 | The Methodist Hospital Research InstituteOTHER | 1 | Mar 30, 2026 | clinicaltrials |
| NCT03663725 | Treatment Intensification With Temozolomide in Adults With a Glioblastoma(StrateGlio) | active not recruiting | Phase 3 | 486 | Centre Oscar LambretOTHER | 1 | Mar 30, 2026 | clinicaltrials |
| NCT04559230 | Sacituzumab Govitecan in Recurrent Glioblastoma | recruiting | Phase 2 | 32 | The University of Texas Health Science Center at San AntonioOTHER | 1 | Mar 30, 2026 | clinicaltrials |
| NCT07431216 | A Phase 1b/2a Study to Evaluate the Safety, Pharmacokinetics, and Objective Response of STAR-001 (LP-184) in Combination With Spironolactone in Supratentorial Glioblastoma at First Progression | not yet recruiting | Phase 1 / Phase 2 | 68 | Starlight Therapeutics Inc.INDUSTRY | 0 | Mar 30, 2026 | clinicaltrials |
| NCT03605550 | A Phase 1b Study of PTC596 in Children With Newly Diagnosed Diffuse Intrinsic Pontine Glioma and High Grade Glioma | active not recruiting | Phase 1 | 64 | Nationwide Children's HospitalOTHER | 1 | Mar 27, 2026 | clinicaltrials |
| NCT02586857 | A Phase 1b/2, Multicenter, Open-label Study of ACP-196 in Subjects With Recurrent Glioblastoma Multiforme (GBM) | active not recruiting | Phase 1 / Phase 2 | 24 | Acerta Pharma BVINDUSTRY | 1 | Mar 25, 2026 | clinicaltrials |
| NCT04574856 | Multiparametric MR-Guided High Dose Adaptive Radiotherapy With Concurrent Temozolomide in Patients With Newly Diagnosed Glioblastoma | active not recruiting | Phase 2 | 30 | University of Michigan Rogel Cancer CenterOTHER | 1 | Mar 25, 2026 | clinicaltrials |
| NCT07492836 | Hypofractionated Radiotherapy Plus Temozolamide in Patients Younger Than 70 Years With Glioblastoma(HipoGBM) | not yet recruiting | N/A | 10 | Hospital do CoracaoOTHER | 0 | Mar 25, 2026 | clinicaltrials |
| NCT05413304 | Abemaciclib Neuropharmacokinetics of Diffuse Midline Glioma Using Intratumoral Microdialysis | active not recruiting | Phase 1 | 1 | National Cancer Institute (NCI)NIH | 1 | Mar 24, 2026 | clinicaltrials |
| NCT06482905 | Safety and Efficacy Study of TX103 CAR-T Cell Therapy for Recurrent or Progressive Grade 4 Glioma. | recruiting | Phase 1 | 52 | Tcelltech Inc.INDUSTRY | 2 | Mar 24, 2026 | clinicaltrials |
| NCT06763965 | Evaluating the Safety and Efficacy of BioTTT001 in Patients With Recurrent/Progressive High-grade Glioma. | enrolling by invitation | Phase 1 / Phase 2 | 30 | Beijing Bio-Targeting Therapeutics Technology Co., LtdINDUSTRY | 1 | Mar 23, 2026 | clinicaltrials |
| NCT07089758 | A Study for Cerebral Open Flow Microperfusion | not yet recruiting | N/A | 6 | Mayo ClinicOTHER | 1 | Mar 23, 2026 | clinicaltrials |
| NCT07126990 | Clinical Study of a Novel Oncolytic Virus Ad-TD-nsIL12 in the Treatment of Primary High-grade Glioma | enrolling by invitation | Phase 1 / Phase 2 | 40 | Xiaorong WuINDUSTRY | 1 | Mar 23, 2026 | clinicaltrials |
| NCT04458272 | A Study of DS-1001b in Patients With Chemotherapy- and Radiotherapy-Naive IDH1 Mutated WHO Grade II Glioma | active not recruiting | Phase 2 | 25 | Daiichi Sankyo Co., Ltd.INDUSTRY | 1 | Mar 20, 2026 | clinicaltrials |
| NCT05733572 | Safety and Efficacy of the PAINLESS Nerve Growth Factor CHF6467 in Optic Pathway Glioma (OPG)(NGF-OPG) | active not recruiting | Phase 2 | 36 | Benedetto FalsiniOTHER | 1 | Mar 19, 2026 | clinicaltrials |
| NCT07481721 | IL13Rα2 CAR-T Cells Secreting Anti-PD-L1 Antibody for Recurrent Malignant Glioma(APIC-RG) | not yet recruiting | Phase 1 | 24 | Ming YangOTHER | 1 | Mar 19, 2026 | clinicaltrials |
| NCT02375841 | Coping With Glioblastoma: A Study of Communication Between Physicians, Patients, and Caregivers | active not recruiting | — | 309 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Mar 18, 2026 | clinicaltrials |
| NCT04655404 | A Pilot Study of Larotrectinib for Newly-Diagnosed High-Grade Glioma With NTRK Fusion | recruiting | Early Phase 1 | 15 | Nationwide Children's HospitalOTHER | 5 | Mar 18, 2026 | clinicaltrials |
| NCT05500391 | Assessment of Compliance With Monitoring Conducted by a Physician in Person or by a Nurse in Remote Monitoring(SUR-CAN) | recruiting | Phase 2 | 88 | Centre Oscar LambretOTHER | 1 | Mar 18, 2026 | clinicaltrials |
| NCT06725173 | Detailed Phenotypic and Genotype Study to Correlate RB1 Mutations Relating to Primary Ocular Tumors and Secondary Extra-ocular Metastasis. | recruiting | — | 100 | University of WashingtonOTHER | 1 | Mar 18, 2026 | clinicaltrials |
| NCT07480941 | Dual-Targeting CAR-NK Cells for Recurrent/Progressive Glioblastoma and High-Grade Glioma(DUAL-CAR-NK-GB) | recruiting | Phase 1 | 36 | Beijing BiotechINDUSTRY | 1 | Mar 18, 2026 | clinicaltrials |
| NCT04943848 | rHSC-DIPGVax Plus Checkpoint Blockade for the Treatment of Newly Diagnosed DIPG and DMG | recruiting | Phase 1 | 36 | Ann & Robert H Lurie Children's Hospital of ChicagoOTHER | 1 | Mar 17, 2026 | clinicaltrials |
| NCT06926075 | Early Phase Study of KESONOTIDE™in Participants With Solid Tumours(ADVICE) | recruiting | Phase 1 / Phase 2 | 80 | Filamon LTDINDUSTRY | 1 | Mar 17, 2026 | clinicaltrials |
| NCT07476794 | Daily Temozolomide for Elderly Patients With Unmethylated MGMT- Promoter Newly Diagnosed GliOblatoma(TEMPO) | recruiting | Phase 2 | 118 | Sunnybrook Health Sciences CentreOTHER | 1 | Mar 17, 2026 | clinicaltrials |
| NCT07472387 | Impact of Androgen Signaling on the Composition of the Immune Microenvironment in Glioblastomas(Andro-iGlio) | not yet recruiting | N/A | 40 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Mar 16, 2026 | clinicaltrials |
| NCT03749187 | BGB-290 and Temozolomide in Treating Isocitrate Dehydrogenase (IDH)1/2-Mutant Grade I-IV Gliomas(PNOC017) | active not recruiting | Phase 1 | 78 | University of California, San FranciscoOTHER | 1 | Mar 13, 2026 | clinicaltrials |
| NCT07469735 | Vorasidenib Guided by AGX PET in Recurrent/Low-grade Glioma(VANGUARD) | not yet recruiting | N/A | 10 | Huashan HospitalOTHER | 1 | Mar 13, 2026 | clinicaltrials |
| NCT07471100 | Neuromodulation-Induced Cortical Prehabilitation in High Grade Glioma Near the Motor Pathway: Cortical Plasticity Assessed by Navigated Transcranial Magnetic Stimulation (nTMS) | not yet recruiting | N/A | 63 | Azienda Sanitaria dell'Alto AdigeOTHER | 0 | Mar 13, 2026 | clinicaltrials |
| NCT05484622 | Study of Vorasidenib and Pembrolizumab Combination in Recurrent or Progressive IDH-1 Mutant Glioma | active not recruiting | Phase 1 | 60 | Institut de Recherches Internationales ServierOTHER | 1 | Mar 12, 2026 | clinicaltrials |
Data updated 24 days agoSource updated Apr 15, 2026source: clinicaltrials